References
- Matthews DJ, Wilson P. Cerebral palsy. In: Molnar GE, Alexander MA, editors. Pediatric rehabilitation, 3rd edn. Philadelphia, PA: Hanley & Belfus, Inc.; 1999. p 193–217.
- Gilmartin R, Bruce D, Storrs B, Abbott R, Krach L, Ward J, Bloom K, Brooks WH, Johnson DL, Madsen JR, et al. Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial. Journal of Child Neurology 2000;15:71–77.
- Krach LE, Kriel RL, Gilmartin RC, Swift DM, Storrs BB, Abbott R, Ward JD, Bloom KK, Brooks WH, Madsen JR, et al. Hip status in CP after one year of continuous intrathecal baclofen infusion. Pediatric Neurology 2004;30:163–168.
- Abbott R, Johann-Murphy M, Forem S. Childhood spasticity assessment. In: Sindou MP, Abbott IR, Keravel Y, editors. Neurosurgery for spasticity. New York: Springer-Verlag; 1991. p 51–56.
- Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540–542.
- Lee K-C, Carson L, Kinnin E, Patterson V. The Ashworth Scale: A reliable and reproducible method of measuring spasticity. Journal of Neurological Rehabilitation 1989;3:205– 209.
- Russell D, Rosenbaum P, Gowland C, Hardy S, Lane M, Plews N, McGavin H, Cadman D, Jarvis S. GMFM gross motor function measure. Hamilton, ON: Hugh MacMillan Rehabilitation Centre, McMaster University; 1990.
- Russell DJ, Rosenbaum PI, Lane M, Gowland C, Goldsmith CH, Boyce WF, Plews N. Training users in the gross motor function measure: Methodological and practical issues. Physical Therapy 1994; 74:630–636.
- Sampson FC, Hayward A, Evans G, Morton R, Collett B. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. Journal of Neurosurgery 2002;96:1052–1057.
- Rawicki B. Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: Long-term follow-up review of 18 patients. Journal of Neurosurgery 1991;91:733–736.
- Armstrong RW, Steinbok P, Cochrane DD, Kube SD, Fife SE, Farrell K. Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. Journal of Neurosurgery 1997;87:409–414.
- Campbell SK, Almeida GL, Penn RD, Corcos DM. The effects of intrathecally administered baclofen on function in patients with spasticity. Physical Therapy 1995;75:352–362.
- Gerszten PC, Albright AL, Barry MJ. Effect on ambulation of continuous intrathecal baclofen infusion. Pediatric Neurosurgery 1997;27:40–44.
- Stempien L, Tsai T. Intrathecal baclofen pump use for spasticity: a clinical survey. American Journal of Physical Medicine and Rehabilitation 2000;79:536–541.
- Scheinberg AM, O’Flaherty S, Chaseling R, Dexter M. Continuous intrathecal baclofen infusion for children with cerebral palsy: A pilot study. Journal of Paediatrics and Child Health 2001; 37:283–288.
- Meythaler JM, Guin-Renfroe S, Law C, Grabb P, Hadley MN. Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy. Archives of Physical Medicine and Rehabilitation 2001; 82:155–161.
- Campbell WM, Ferrel A, McLaughlin JF, Grant GA, Loeser JD, Graubert C, Bjornson K. Long-term safety and efficacy of continuous intrathecal baclofen. Developmental Medicine and Child Neurology 2002; 44: 660–665.
- Rosenbaum PL, Walter SD, Hanna SE, Palisano RJ, Russell DJ, Raina P, Wood E, Bartlett DJ, Galuppi BE. Prognosis for gross motor function in cerebral palsy: Creation of motor development curves. Journal of the American Medical Association 2002;288:1357–1363.
- Bjornson K, McLaughlin J, Loeser J, et al. Oral motor, communication and nutritional status of children during intrathecal baclofen therapy. Archives of Physical Medicine and Rehabilitation 2003;84:500–506.